ORIC Pharmaceuticals, Inc.
oricpharma.comWhat Do They Do?
Develops cancer drug candidates designed to counter treatment resistance, including therapies for people with prostate and lung cancers.
10-K for FY2025, filed Feb 23, 2026ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In…View ↗
Our fully integrated research and development team is advancing a diverse pipeline of innovative clinical therapies designed to counter…View ↗
Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm…View ↗
Enozertinib (formerly ORIC-114), a brain-penetrant, orally bioavailable, irreversible inhibitor targeting EGFR exon 20 and EGFR atypical…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 23, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 3, 2026
−$41.5MView ↗
- ▲ +14% (Loss)
- vs −$36.4M in Q2 FY2025
Who Do They Compete With?
Competes with Ipsen, Novartis, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical, Treeline Biosciences, Jiangsu HengRui Medicine, Evopoint Biosciences, Hanmi Pharmaceutical, Ascentage Pharma, Johnson & Johnson, Dizal Pharmaceuticals, Cullinan Therapeutics, ArriVent BioPharma, Black Diamond Therapeutics, Scorpion Therapeutics, BlossomHill Therapeutics, Avistone Biotechnology, BeBetter Med, and Yuhan
10-K for FY2025, filed Feb 23, 2026For rinzimetostat, we are aware of several companies developing inhibitors against PRC2 via EZH2 inhibition that are currently in clinical…View ↗
Loading...
